Overview

Belumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-Disease

Status:
RECRUITING
Trial end date:
2027-12-31
Target enrollment:
Participant gender:
Summary
This is an open-label, Phase 2 study designed to evaluate the safety and efficacy of belumosudil and rituximab as primary treatment of cGVHD.
Phase:
PHASE2
Details
Lead Sponsor:
Northside Hospital, Inc.
Collaborator:
Sanofi
Treatments:
belumosudil
Rituximab